PPR-003 - Monitoring and Optimizing Adherence to GLP-1 Analogue Therapy: The Role of Community Pharmacy Interventions

• At: Copenhagen (Denmark) (2025)
• Type: Poster
• Poster code: PPR-003
• By: MEHRDAD, Arjang (Stevns Apotek, Denmark)
• Co-author(s): Mr Arjang Mehrdad (Stevns Apotek, Store Heddinge, Denmark)
  Stud.pharm Ava Mehrdad
  
• Abstract:

  Background: Glucagon-like peptide-1 (GLP-1) analogues, including Wegovy® (semaglutid) and Ozempic® (semaglutid) have become an integral part of obesity and type 2 diabetes (T2DM) management worldwide. In December 2022, Wegovy® received approval for obesity treatment in Denmark, contributing to a rising number of patients being initiated on..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login